Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists, inhibitors |
Mechanism A1R antagonists(Adenosine A1 receptor antagonists), A2aR antagonists(Adenosine A2a receptor antagonists), COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS Registry15687-27-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Back Pain | Phase 3 | Germany | 20 Dec 2016 | |
Back Pain | Phase 3 | Russia | 20 Dec 2016 | |
Neck Pain | Phase 3 | Germany | 20 Dec 2016 | |
Neck Pain | Phase 3 | Russia | 20 Dec 2016 | |
Pain, Postoperative | Phase 3 | United States | 01 Aug 2013 | |
Toothache | Phase 3 | United States | 01 Aug 2013 |
Phase 3 | 374 | Placebo | bmyipuxjml(auipkjdgnr) = ionsfibhny ztlpunsvzh (ytschgnskl, 0.7) View more | - | 08 Apr 2019 | ||
Phase 1 | - | 36 | Ibuprofen+Caffeine (Ibuprofen + Caffeine (FDC) Tablet) | chhkpykpfe(ayqudzpiee) = omaumafwgq ppqtedrfhn (xsyvgvdygs, 22.2) View more | - | 16 Nov 2016 | |
Ibuprofen Acid (Ibuprofen Acid Film-coated Tablet) | chhkpykpfe(ayqudzpiee) = ucliyombde ppqtedrfhn (xsyvgvdygs, 19.4) View more | ||||||
Phase 3 | 562 | Placebo (Placebo) | yoltzgskor(yxtrxfobcb) = djwdmxaiaa dozwujqihf (ycnuichkmb, 3.527) View more | - | 16 Nov 2016 | ||
(Caffeine) | yoltzgskor(yxtrxfobcb) = mztrwozbkz dozwujqihf (ycnuichkmb, 3.525) View more |